Citadel Advisors
CRDF icon

Citadel Advisors’s Cardiff Oncology CRDF Stock Holding History

Citadel Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$371K Sell
229,000
-43,800
-16% -$89.9K ﹤0.01% 9981
2025
Q4 		$767K Buy
272,800
+44,900
+20% +$104K ﹤0.01% 8011
2025
Q3 		$469K Buy
227,900
+142,300
+166% +$393K ﹤0.01% 9284
2025
Q2 		$270K Buy
85,600
+44,200
+107% +$135K ﹤0.01% 10047
2025
Q1 		$130K Sell
41,400
-86,500
-68% -$342K ﹤0.01% 11086
2024
Q4 		$555K Buy
127,900
+122,000
+2,068% +$381K ﹤0.01% 8328
2024
Q3 		$15.8K Sell
5,900
-18,000
-75% -$42.5K ﹤0.01% 12954
2024
Q2 		$53.1K Sell
23,900
-2,600
-10% -$9.8K ﹤0.01% 11690
2024
Q1 		$142K Buy
26,500
+19,000
+253% +$50.5K ﹤0.01% 10854
2023
Q4 		$11.1K Sell
7,500
-12,800
-63% -$15.5K ﹤0.01% 13058
2023
Q3 		$28.2K Buy
20,300
+10,200
+101% +$17.2K ﹤0.01% 12332
2023
Q2 		$14.8K Buy
10,100
+6,400
+173% +$10.3K ﹤0.01% 12983
2023
Q1 		$6.11K Buy
3,700
+1,200
+48% +$2.06K ﹤0.01% 13829
2022
Q4 		$3.5K Sell
2,500
-53,300
-96% -$76.3K ﹤0.01% 14203
2022
Q3 		$86K Buy
+55,800
New +$134K ﹤0.01% 11218
2022
Q1 		– Sell
-41,400
Closed -$249K – 13716
2021
Q4 		$249K Buy
41,400
+8,900
+27% +$53K ﹤0.01% 11365
2021
Q3 		$216K Sell
32,500
-12,900
-28% -$81K ﹤0.01% 11824
2021
Q2 		$302K Sell
45,400
-78,900
-63% -$669K ﹤0.01% 11254
2021
Q1 		$1.15M Buy
124,300
+23,700
+24% +$288K ﹤0.01% 7753
2020
Q4 		$1.81M Buy
100,600
+28,100
+39% +$494K ﹤0.01% 5536
2020
Q3 		$1.03M Buy
+72,500
New +$479K ﹤0.01% 5981
2016
Q4 		– Sell
-178
Closed -$57K – 7308
2016
Q3 		$57K Buy
+178
New +$64.9K ﹤0.01% 6828

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Citadel Advisors's CRDF Position: Q1 2026 in Review

Citadel Advisors increased its Cardiff Oncology (CRDF) stake by 6.2% in Q1 2026, buying an estimated $15.2K and bringing the position to 125,566 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #11391.

Citadel Advisors first reported a position in CRDF in Q1 2014 and has held it in 27 quarters since. The position peaked at $15.6M in Q4 2020. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Citadel Advisors held 125,566 shares of Cardiff Oncology worth $203K as of Q1 2026.
  • Citadel Advisors bought 7,378 Cardiff Oncology shares in Q1 2026, an estimated $15.2K.
  • Cardiff Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11391 holding.
  • Citadel Advisors first reported a position in Cardiff Oncology in Q1 2014 and has held it in 27 quarters since.
  • Citadel Advisors's Cardiff Oncology position peaked at $15.6M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.